4//SEC Filing
Hirano Patricia C 4
Accession 0001415889-25-009291
CIK 0001484565other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 7:01 PM ET
Size
63.0 KB
Accession
0001415889-25-009291
Insider Transaction Report
Form 4
Hirano Patricia C
SEE REMARKS
Transactions
- Exercise/Conversion
Common Stock
2025-03-27$24.00/sh+6,000$144,000→ 100,773 total - Exercise/Conversion
Common Stock
2025-03-27$2.60/sh+13,333$34,599→ 123,394 total - Sale
Common Stock
2025-03-27$69.84/sh−3,198$223,339→ 95,653 total - Sale
Common Stock
2025-03-27$72.64/sh−73$5,303→ 94,773 total - Exercise/Conversion
Common Stock
2025-03-27$5.25/sh+35,186$184,727→ 166,913 total - Sale
Common Stock
2025-03-27$70.18/sh−24,989$1,753,628→ 70,934 total - Exercise/Conversion
Common Stock
2025-03-28$33.60/sh+2,691$90,418→ 58,480 total - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−6,000→ 0 totalExercise: $24.00Exp: 2028-02-07→ Common Stock (6,000 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−8,333→ 11,667 totalExercise: $2.41Exp: 2033-01-25→ Common Stock (8,333 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−35,186→ 49,262 totalExercise: $5.25Exp: 2033-05-26→ Common Stock (35,186 underlying) - Exercise/Conversion
Common Stock
2025-03-27$2.41/sh+8,333$20,083→ 131,727 total - Sale
Common Stock
2025-03-28$67.46/sh−3,394$228,946→ 55,086 total - Sale
Common Stock
2025-03-28$68.92/sh−12,324$849,386→ 42,762 total - Sale
Common Stock
2025-03-28$73.60/sh−2,691$198,058→ 30,818 total - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−4,400→ 0 totalExercise: $25.05Exp: 2029-01-24→ Common Stock (4,400 underlying) - Exercise/Conversion
Common Stock
2025-03-27$5.10/sh+4,888$24,929→ 110,061 total - Sale
Common Stock
2025-03-27$67.47/sh−24,776$1,671,629→ 95,923 total - Sale
Common Stock
2025-03-27$72.50/sh−15,145$1,098,013→ 55,789 total - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−4,888→ 2,445 totalExercise: $5.10Exp: 2032-01-28→ Common Stock (4,888 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−13,333→ 0 totalExercise: $2.60Exp: 2032-07-27→ Common Stock (13,333 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-03-28−2,691→ 18,842 totalExercise: $33.60Exp: 2031-01-08→ Common Stock (2,691 underlying) - Sale
Common Stock
2025-03-27$66.79/sh−2,310$154,289→ 108,574 total - Sale
Common Stock
2025-03-27$67.70/sh−4,199$284,275→ 104,375 total - Sale
Common Stock
2025-03-27$68.79/sh−5,524$379,985→ 98,851 total - Sale
Common Stock
2025-03-27$70.73/sh−329$23,272→ 95,324 total - Sale
Common Stock
2025-03-27$71.74/sh−478$34,293→ 94,846 total - Sale
Common Stock
2025-03-27$66.39/sh−46,214$3,068,147→ 120,699 total - Sale
Common Stock
2025-03-28$69.52/sh−9,253$643,246→ 33,509 total - Sale
Common Stock
2025-03-27$65.97/sh−1,418$93,544→ 110,884 total - Exercise/Conversion
Common Stock
2025-03-27$25.05/sh+4,400$110,220→ 105,173 total
Footnotes (21)
- [F1]These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F10]This transaction was executed in multiple trades at prices ranging from $72.31 to $72.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F11]The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person September 13, 2024
- [F12]This transaction was executed in multiple trades at prices ranging from 67.41 to $67.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F13]This transaction was executed in multiple trades at prices ranging from $70.00 to $70.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F14]This transaction was executed in multiple trades at prices ranging from $66.90 to $67.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F15]This transaction was executed in multiple trades at prices ranging from $68.30 to $69.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F16]This transaction was executed in multiple trades at prices ranging from $69.33 to $69.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F17]All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- [F18]One forty-eighth (1/48th) of the shares subject to the Option vest on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
- [F19]One forty-eighth of the shares subject to the option vest on February 1, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
- [F2]This transaction was executed in multiple trades at prices ranging from $65.15 to $66.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F20]One thirty-sixth of the shares subject to the Option vest on June 26, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.
- [F21]Twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
- [F3]Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- [F4]This transaction was executed in multiple trades at prices ranging from $66.24 to $67.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $67.24 to $68.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F6]This transaction was executed in multiple trades at prices ranging from $68.24 to $69.225. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F7]This transaction was executed in multiple trades at prices ranging from $69.24 to $70.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F8]This transaction was executed in multiple trades at prices ranging from $70.24 to $71.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F9]This transaction was executed in multiple trades at prices ranging from $71.26 to $72.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Documents
Issuer
SOLENO THERAPEUTICS INC
CIK 0001484565
Entity typeother
Related Parties
1- filerCIK 0001766042
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 7:01 PM ET
- Size
- 63.0 KB